E.ShimadaK.SkoutaR.ViswanathanV
Avoid scars, moles, veins, stretch marks, and previously irritated areas
Right now, taking a GLP-1 drug is like hiring someone to come to your house every week and refill your water tank
This month's Broker Brief breaks down: - Why up to 65% of GLP-1 users discontinue within a year, and why that turns coverage into a sunk cost for employers - What oral GLP-1s like Lilly's Foundayo mean for demand, when most plans still have eligibility rules written for injectables only - How fast a PBM formulary decision can move, using this year's Zepbound to Wegovy switch and back as the case in point - Why 38% of employers already tie GLP-1 coverage to participation in a lifestyle or behavioral program If you're advising employers on GLP-1 coverage, this is where the conversation is heading
Emerging evidence suggests that GLP-1 RAs modulate hormonal balance, lipid metabolism, and inflammatory pathways, offering potential therapeutic benefits in reproductive health and menopause-related metabolic changes